These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions. Dan K; Garcia-Garcia HM; Kolm P; Windecker S; Saito S; Kandzari DE; Waksman R Circ Cardiovasc Interv; 2020 Sep; 13(9):e009189. PubMed ID: 32895004 [TBL] [Abstract][Full Text] [Related]
6. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial. Zbinden R; Piccolo R; Heg D; Roffi M; Kurz DJ; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Franzone A; Eberli F; Jüni P; Windecker S; Pilgrim T J Am Heart Assoc; 2016 Mar; 5(3):e003255. PubMed ID: 26979080 [TBL] [Abstract][Full Text] [Related]
7. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization. Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590 [TBL] [Abstract][Full Text] [Related]
8. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. Iglesias JF; Heg D; Roffi M; Tüller D; Noble S; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Häner J; Jüni P; Windecker S; Pilgrim T Circ Cardiovasc Interv; 2019 Aug; 12(8):e008024. PubMed ID: 31525083 [TBL] [Abstract][Full Text] [Related]
9. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent). Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236 [TBL] [Abstract][Full Text] [Related]
10. Bioresorbable polymer-coated thin strut sirolimus-eluting stent vs durable polymer-coated everolimus-eluting stent in daily clinical practice: Propensity matched one-year results from interventional cardiology network registry. Gasior P; Gierlotka M; Szczurek-Katanski K; Osuch M; Gnot R; Hawranek M; Gasior M; Polonski L Catheter Cardiovasc Interv; 2019 Jun; 93(7):E362-E368. PubMed ID: 30298545 [TBL] [Abstract][Full Text] [Related]
11. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT. Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Danse PW; Schotborgh CE; Scholte M; van Houwelingen KG; Stoel MG; Hartmann M; Tjon Joe Gin RM; Somi S; Linssen GCM; Kok MM; von Birgelen C JACC Cardiovasc Interv; 2019 Sep; 12(17):1650-1660. PubMed ID: 31422087 [TBL] [Abstract][Full Text] [Related]
12. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial. Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus. Waksman R; Shlofmitz E; Windecker S; Koolen JJ; Saito S; Kandzari D; Kolm P; Lipinski MJ; Torguson R Am J Cardiol; 2019 Oct; 124(7):1020-1026. PubMed ID: 31353004 [TBL] [Abstract][Full Text] [Related]
14. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. Iglesias JF; Heg D; Roffi M; Tüller D; Lanz J; Rigamonti F; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Valgimigli M; Jüni P; Windecker S; Pilgrim T J Am Heart Assoc; 2019 Nov; 8(22):e013607. PubMed ID: 31696762 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the Ultrathin Strut, Biodegradable Polymer Sirolimus-eluting Stent With a Durable Polymer Everolimus-eluting Stent in a Chinese Population: The Randomized BIOFLOW VI Trial. Li C; Yang Y; Han Y; Song D; Xu J; Guan C; Gao R; Garcia-Garcia HM; Waksman R; Xu B; Clin Ther; 2020 Apr; 42(4):649-660.e9. PubMed ID: 32268942 [TBL] [Abstract][Full Text] [Related]
16. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease. Kufner S; Joner M; Thannheimer A; Hoppmann P; Ibrahim T; Mayer K; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Byrne RA; Circulation; 2019 Jan; 139(3):325-333. PubMed ID: 30586724 [TBL] [Abstract][Full Text] [Related]
17. Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial. Iñiguez A; Chevalier B; Richardt G; Neylon A; Jiménez VA; Kornowski R; Carrie D; Moreno R; Barbato E; Serra-Peñaranda A; Guiducci V; Valdés-Chávarri M; Yajima J; Wijns W; Saito S; Catheter Cardiovasc Interv; 2020 Feb; 95(2):175-184. PubMed ID: 31033154 [TBL] [Abstract][Full Text] [Related]
18. Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: 5-Year Outcomes of the Randomized BIOFLOW-II Trial. Lefèvre T; Haude M; Neumann FJ; Stangl K; Skurk C; Slagboom T; Sabaté M; Goicolea J; Barragan P; Cook S; Macia JC; Windecker S JACC Cardiovasc Interv; 2018 May; 11(10):995-1002. PubMed ID: 29798778 [TBL] [Abstract][Full Text] [Related]